A randomized, double-blind, placebo controlled, 4-period 4-treatment crossover, multi-center, single dose, dose ranging study followed by a single day's treatment with open label salmeterol bid (100 microg/day), to assess the efficacy and safety of 3 doses of indacaterol (150, 300 and 600 microg) delivered via SDDPI [single dose dry powder inhaler] in Japanese asthma patients.

Trial Profile

A randomized, double-blind, placebo controlled, 4-period 4-treatment crossover, multi-center, single dose, dose ranging study followed by a single day's treatment with open label salmeterol bid (100 microg/day), to assess the efficacy and safety of 3 doses of indacaterol (150, 300 and 600 microg) delivered via SDDPI [single dose dry powder inhaler] in Japanese asthma patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2016

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 17 Sep 2008 Actual patient number (41) added as reported by ClinicalTrials.gov.
    • 03 Dec 2007 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 08 Aug 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top